Hai Phong Pharmaceutical Joint Stock Co
UUPCOM:DPH39,100.00
VND
-6,400.00
(-14.07%)
ISIN
VN000000DPH1
Return %
Stock
S&P 500
1Y
-32.59
14.20
3Y
2.89
81.12
5Y
-17.34
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Haiphong Vietnam
- IPO Date
- Jan 20, 2017
- Website
- haipharco.vn
- Similar Companies
- Business
- Hai Phong Pharmaceutical Joint Stock Company (UPCoM: DPH), commonly known as Haipharco, is a Vietnam-based pharmaceutical manufacturing and trading enterprise engaged in the development, production, marketing, and distribution of modern pharmaceuticals, traditional herbal medicines, dietary supplements, and medical supplies. Founded in 1961 as the Hai Phong Pharmaceutical State Enterprise and restructured into a joint-stock company in 2005, the company is headquartered in Hai Phong, Vietnam. Haipharco operates through multiple specialized manufacturing and commercial segments, offering products and services that include ophthalmic and nasal preparations, comprising sodium chloride solutions, Haiphaxeda eye drops, Oxacol nasal spray, and Ospay Neo decongestant spray; solid dosage non-beta-lactam pharmaceuticals, including Sedachor tablets, hard capsules, soft gelatin capsules, and oral granules; traditional herbal formulations and functional supplements, including Hoan Bo Than Am kidney-nourishing pills, Hoat Huyet Duong Nao cerebral circulation enhancers, MTD liver-detoxifying remedies, Philatop nutritional tonics, and Ruou Phong Thap herbal tinctures; topical antiseptics and disinfectants, such as Povidone Iodine 10% solution; and pharmaceutical trading and commercial distribution services, encompassing wholesale supply to healthcare institutions, hospitals, retail pharmacies, and regional medical distributors, as well as the commercial distribution of medical instruments, consumable medical supplies, and medicinal botanical raw materials. The company operates manufacturing facilities adhering to Good Manufacturing Practice (GMP-WHO), Good Laboratory Practice (GLP), and Good Storage Practice (GSP) standards located in Kien An District, Hai Phong, and maintains a domestic distribution network covering Hai Phong, Hanoi, and broader northern and central Vietnamese markets. In recent company developments, Haipharco has executed strategic and operational adjustments including board-approved debt restructuring resolutions with commercial banking partners, expanded and upgraded its GMP-WHO compliant soft gelatin capsule and herbal medicine production lines to increase output capacity, maintained strong shareholder capital returns with consistent cash dividend payouts ranging between 15% and 20%, and initiated corporate governance updates for its 2026–2031 administrative tenure to accelerate commercial penetration and expand its institutional hospital and retail pharmacy supply contracts across Vietnam.